Treatment outcomes of risperidone long acting injection (RLAI) in schizophrenia: 18-month results from the electronic schizophrenia treatment adherence registry (E-STAR) in Czech Republic and Slovakia

被引：0
|
作者：
Tuma, I [1 ]
Pecenak, J. [2 ]
Povey, M. [3 ]
Lam, A. [4 ]
Zhao, Z. [5 ]
机构：
[1] FNSP Hradec Kralove, Hradec Kralove, Czech Republic
[2] FNSP Bratislava, Bratislava, Slovakia
[3] SGS Biopharma, Wavre, Belgium
[4] JJPS, Toronto, ON, Canada
[5] Johnson & Johnson Pharmaceut Serv, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)70362-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A112 / A113
页数：2
相关论文
共 50 条
  • [1] RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA: 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA
    Lyubov, E.
    Dzhatdoeva, A.
    Zhao, Z.
    Cain, J.
    VALUE IN HEALTH, 2008, 11 (06) : A579 - A580
  • [2] Risperidone long-acting injection (RLAI) in the treatment of schizophrenia: 12 month preliminary results from e-STAR project in Czech Republic and Slovakia
    Pecenak, J.
    Tuma, I
    Povey, M.
    Lam, A.
    VALUE IN HEALTH, 2007, 10 (06) : A290 - A290
  • [3] Risperidone long acting injection treatment in schizophrenia: 12-month results from the electronic Schizophrenia Treatment Adherence Registry (E-STAR)
    Alexandrov, A.
    Olivares, Jose
    Tuma, Ivan
    Peuskens, Jos
    Pecenaks, Jan
    Eriksson, Lars
    Bork, B.
    Povey, Michael
    Lam, Annette
    Trakas, Kostas
    Zhao, Zhongyun
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 280S - 280S
  • [4] Risperidone long acting injection treatment in schizophrenia: 12-month results from the electronic schizophrenia treatment adherence registry (E-STAR)
    Zhao, Z.
    Alexandrov, A.
    Olivares, J. M.
    Tuma, I.
    Peuskens, J.
    Pecenak, J.
    Eriksson, L.
    Bork, B.
    Povey, M.
    Lam, A.
    Trakas, K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 160 - 160
  • [5] Treatment retention with risperidone long acting injection (RLAI) in European patients with schizophrenia: 12-month interim results from electronic Schizophrenia Treatment Adherence Registry (e-STAR)
    Olivares, J. M.
    Peuskens, J.
    Pecenak, J.
    Tuma, I
    Van Kooten, M.
    Eriksson, L.
    Povey, M.
    Lam, A.
    Zhao, Z.
    VALUE IN HEALTH, 2007, 10 (06) : A290 - A290
  • [6] 24-month treatment discontinuation rates in patients with schizophrenia treated with risperidone long acting injection (RLAI) versus oral antipsychotics: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR) in Spain
    Olivares, J. M.
    Diels, J. K.
    Rodriguez-Morales, A.
    Zhao, Z.
    Lam, A.
    VALUE IN HEALTH, 2007, 10 (06) : A291 - A291
  • [7] Risperidone long-acting injection (RLAI) in the treatment of schizophrenia: 3 month preliminary results from e-STAR project in Canada
    Costigan, N.
    Ligate, L.
    Povey, M.
    Lam, A.
    VALUE IN HEALTH, 2007, 10 (06) : A289 - A289
  • [8] Improvements in illness severity and functioning in patients with schizophrenia treated with risperidone long-acting injection (RLAI): 18 month interim results from belgian patients enrolled in the electronic Schizophrenia Treatment Adherence Registry (e-STAR)
    Peukens, J.
    Povey, M.
    Van der Veken, J.
    Lam, A.
    VALUE IN HEALTH, 2007, 10 (06) : A291 - A291
  • [9] Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries
    Peuskens, J.
    Olivares, J. M.
    Pecenak, J.
    Tuma, I.
    de Weg, H. Bij
    Eriksson, L.
    Resseler, S.
    Akhras, K.
    Jacobs, A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (03) : 501 - 509
  • [10] Long acting injectable risperidone in the treatment of schizophrenia: 6 month preliminary results in E-star project in Czech Republic
    Tuma, I.
    Povey, M.
    Lam, A.
    EUROPEAN PSYCHIATRY, 2007, 22 : S170 - S170
12345